nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—SLC6A3—malignant glioma	0.665	1	CbGaD
Atomoxetine—HTR1D—meninx—malignant glioma	0.0211	0.121	CbGeAlD
Atomoxetine—HTR1B—dura mater—malignant glioma	0.02	0.115	CbGeAlD
Atomoxetine—HTR1D—dura mater—malignant glioma	0.0194	0.111	CbGeAlD
Atomoxetine—HTR2C—choroid plexus—malignant glioma	0.0163	0.0939	CbGeAlD
Atomoxetine—HTR2A—choroid plexus—malignant glioma	0.00819	0.0471	CbGeAlD
Atomoxetine—HTR1B—telencephalic ventricle—malignant glioma	0.00499	0.0287	CbGeAlD
Atomoxetine—SLC6A3—telencephalic ventricle—malignant glioma	0.00495	0.0284	CbGeAlD
Atomoxetine—HTR1D—telencephalic ventricle—malignant glioma	0.00483	0.0278	CbGeAlD
Atomoxetine—HTR2C—telencephalic ventricle—malignant glioma	0.00478	0.0275	CbGeAlD
Atomoxetine—HTR2A—cerebellar cortex—malignant glioma	0.00412	0.0237	CbGeAlD
Atomoxetine—Abnormal behaviour—Temozolomide—malignant glioma	0.00328	0.054	CcSEcCtD
Atomoxetine—HTR2A—pons—malignant glioma	0.00292	0.0168	CbGeAlD
Atomoxetine—HTR2A—vertebral column—malignant glioma	0.00289	0.0166	CbGeAlD
Atomoxetine—NPY1R—telencephalon—malignant glioma	0.00282	0.0162	CbGeAlD
Atomoxetine—HTR1B—blood vessel—malignant glioma	0.00247	0.0142	CbGeAlD
Atomoxetine—HTR2A—telencephalic ventricle—malignant glioma	0.0024	0.0138	CbGeAlD
Atomoxetine—HTR1D—blood vessel—malignant glioma	0.00239	0.0137	CbGeAlD
Atomoxetine—HTR2A—pineal body—malignant glioma	0.00208	0.012	CbGeAlD
Atomoxetine—HTR6—telencephalon—malignant glioma	0.00199	0.0114	CbGeAlD
Atomoxetine—NPY1R—central nervous system—malignant glioma	0.0016	0.00923	CbGeAlD
Atomoxetine—Rigors—Temozolomide—malignant glioma	0.0015	0.0246	CcSEcCtD
Atomoxetine—Drug interaction—Carmustine—malignant glioma	0.00136	0.0224	CcSEcCtD
Atomoxetine—HTR1B—brainstem—malignant glioma	0.00135	0.00776	CbGeAlD
Atomoxetine—SLC6A3—brainstem—malignant glioma	0.00134	0.0077	CbGeAlD
Atomoxetine—HTR1D—brainstem—malignant glioma	0.00131	0.00751	CbGeAlD
Atomoxetine—HTR2C—brainstem—malignant glioma	0.00129	0.00744	CbGeAlD
Atomoxetine—HTR2A—endothelium—malignant glioma	0.00129	0.0074	CbGeAlD
Atomoxetine—NPY1R—brain—malignant glioma	0.00127	0.00733	CbGeAlD
Atomoxetine—SLC6A4—brainstem—malignant glioma	0.00123	0.00705	CbGeAlD
Atomoxetine—HTR1B—telencephalon—malignant glioma	0.0012	0.00689	CbGeAlD
Atomoxetine—SLC6A3—telencephalon—malignant glioma	0.00119	0.00683	CbGeAlD
Atomoxetine—HTR2A—blood vessel—malignant glioma	0.00119	0.00683	CbGeAlD
Atomoxetine—HTR1D—telencephalon—malignant glioma	0.00116	0.00667	CbGeAlD
Atomoxetine—Coma—Carmustine—malignant glioma	0.00116	0.019	CcSEcCtD
Atomoxetine—HTR2C—telencephalon—malignant glioma	0.00115	0.0066	CbGeAlD
Atomoxetine—HTR6—central nervous system—malignant glioma	0.00113	0.00649	CbGeAlD
Atomoxetine—SLC6A4—telencephalon—malignant glioma	0.00109	0.00626	CbGeAlD
Atomoxetine—SLC6A2—brainstem—malignant glioma	0.00108	0.00621	CbGeAlD
Atomoxetine—Hepatic failure—Temozolomide—malignant glioma	0.000988	0.0163	CcSEcCtD
Atomoxetine—Nasal congestion—Temozolomide—malignant glioma	0.000975	0.016	CcSEcCtD
Atomoxetine—SLC6A2—telencephalon—malignant glioma	0.000958	0.00551	CbGeAlD
Atomoxetine—Hot flush—Temozolomide—malignant glioma	0.000949	0.0156	CcSEcCtD
Atomoxetine—Menopausal symptoms—Temozolomide—malignant glioma	0.000941	0.0155	CcSEcCtD
Atomoxetine—Thirst—Temozolomide—malignant glioma	0.000933	0.0153	CcSEcCtD
Atomoxetine—HTR2C—medulla oblongata—malignant glioma	0.000902	0.00519	CbGeAlD
Atomoxetine—HTR6—brain—malignant glioma	0.000897	0.00516	CbGeAlD
Atomoxetine—Affect lability—Temozolomide—malignant glioma	0.000874	0.0144	CcSEcCtD
Atomoxetine—HTR1B—midbrain—malignant glioma	0.00086	0.00495	CbGeAlD
Atomoxetine—SLC6A3—midbrain—malignant glioma	0.000853	0.0049	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—malignant glioma	0.000849	0.0894	CrCbGaD
Atomoxetine—Mood swings—Temozolomide—malignant glioma	0.000841	0.0138	CcSEcCtD
Atomoxetine—HTR1B—spinal cord—malignant glioma	0.000839	0.00482	CbGeAlD
Atomoxetine—HTR1D—midbrain—malignant glioma	0.000833	0.00479	CbGeAlD
Atomoxetine—SLC6A3—spinal cord—malignant glioma	0.000832	0.00479	CbGeAlD
Atomoxetine—HTR2C—midbrain—malignant glioma	0.000825	0.00474	CbGeAlD
Atomoxetine—HTR2C—spinal cord—malignant glioma	0.000805	0.00463	CbGeAlD
Atomoxetine—Breast disorder—Temozolomide—malignant glioma	0.000802	0.0132	CcSEcCtD
Atomoxetine—SLC6A4—midbrain—malignant glioma	0.000782	0.00449	CbGeAlD
Atomoxetine—SLC6A4—spinal cord—malignant glioma	0.000763	0.00439	CbGeAlD
Atomoxetine—Benzphetamine—POR—malignant glioma	0.000755	0.0796	CrCbGaD
Atomoxetine—SLC6A2—medulla oblongata—malignant glioma	0.000753	0.00433	CbGeAlD
Atomoxetine—Sweating increased—Temozolomide—malignant glioma	0.000747	0.0123	CcSEcCtD
Atomoxetine—Dysuria—Temozolomide—malignant glioma	0.000718	0.0118	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000713	0.0117	CcSEcCtD
Atomoxetine—Pollakiuria—Temozolomide—malignant glioma	0.000709	0.0117	CcSEcCtD
Atomoxetine—HTR2A—embryo—malignant glioma	0.000708	0.00407	CbGeAlD
Atomoxetine—Erectile dysfunction—Temozolomide—malignant glioma	0.000707	0.0116	CcSEcCtD
Atomoxetine—Depression—Carmustine—malignant glioma	0.000706	0.0116	CcSEcCtD
Atomoxetine—Weight decreased—Temozolomide—malignant glioma	0.000694	0.0114	CcSEcCtD
Atomoxetine—Infestation—Temozolomide—malignant glioma	0.000684	0.0113	CcSEcCtD
Atomoxetine—Infestation NOS—Temozolomide—malignant glioma	0.000684	0.0113	CcSEcCtD
Atomoxetine—Depression—Temozolomide—malignant glioma	0.000682	0.0112	CcSEcCtD
Atomoxetine—HTR1B—central nervous system—malignant glioma	0.000681	0.00391	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—malignant glioma	0.000675	0.00388	CbGeAlD
Atomoxetine—SLC6A3—cerebellum—malignant glioma	0.00066	0.00379	CbGeAlD
Atomoxetine—HTR1D—central nervous system—malignant glioma	0.000659	0.00379	CbGeAlD
Atomoxetine—HTR2C—central nervous system—malignant glioma	0.000653	0.00375	CbGeAlD
Atomoxetine—HTR2A—brainstem—malignant glioma	0.000649	0.00373	CbGeAlD
Atomoxetine—Sinusitis—Temozolomide—malignant glioma	0.000642	0.0106	CcSEcCtD
Atomoxetine—Hypoaesthesia—Carmustine—malignant glioma	0.000632	0.0104	CcSEcCtD
Atomoxetine—Hallucination—Carmustine—malignant glioma	0.000632	0.0104	CcSEcCtD
Atomoxetine—HTR2A—retina—malignant glioma	0.000626	0.0036	CbGeAlD
Atomoxetine—SLC6A4—central nervous system—malignant glioma	0.000619	0.00356	CbGeAlD
Atomoxetine—Hypoaesthesia—Temozolomide—malignant glioma	0.000611	0.0101	CcSEcCtD
Atomoxetine—Hallucination—Temozolomide—malignant glioma	0.000611	0.0101	CcSEcCtD
Atomoxetine—Urinary tract disorder—Temozolomide—malignant glioma	0.000607	0.00998	CcSEcCtD
Atomoxetine—Urethral disorder—Temozolomide—malignant glioma	0.000602	0.0099	CcSEcCtD
Atomoxetine—CYP2D6—brainstem—malignant glioma	0.000591	0.0034	CbGeAlD
Atomoxetine—Flushing—Carmustine—malignant glioma	0.00059	0.0097	CcSEcCtD
Atomoxetine—HTR2A—telencephalon—malignant glioma	0.000576	0.00331	CbGeAlD
Atomoxetine—Flushing—Temozolomide—malignant glioma	0.00057	0.00938	CcSEcCtD
Atomoxetine—Cardiac disorder—Temozolomide—malignant glioma	0.00057	0.00938	CcSEcCtD
Atomoxetine—Angiopathy—Temozolomide—malignant glioma	0.000557	0.00917	CcSEcCtD
Atomoxetine—Mental disorder—Carmustine—malignant glioma	0.000557	0.00916	CcSEcCtD
Atomoxetine—Mediastinal disorder—Temozolomide—malignant glioma	0.000554	0.00911	CcSEcCtD
Atomoxetine—Malnutrition—Carmustine—malignant glioma	0.000553	0.0091	CcSEcCtD
Atomoxetine—Chills—Temozolomide—malignant glioma	0.000551	0.00907	CcSEcCtD
Atomoxetine—SLC6A2—central nervous system—malignant glioma	0.000545	0.00313	CbGeAlD
Atomoxetine—HTR1B—brain—malignant glioma	0.00054	0.00311	CbGeAlD
Atomoxetine—Mental disorder—Temozolomide—malignant glioma	0.000538	0.00885	CcSEcCtD
Atomoxetine—SLC6A3—brain—malignant glioma	0.000536	0.00308	CbGeAlD
Atomoxetine—Back pain—Carmustine—malignant glioma	0.000535	0.0088	CcSEcCtD
Atomoxetine—Malnutrition—Temozolomide—malignant glioma	0.000535	0.00879	CcSEcCtD
Atomoxetine—CYP2D6—telencephalon—malignant glioma	0.000525	0.00302	CbGeAlD
Atomoxetine—Dysgeusia—Temozolomide—malignant glioma	0.000524	0.00861	CcSEcCtD
Atomoxetine—HTR1D—brain—malignant glioma	0.000523	0.00301	CbGeAlD
Atomoxetine—Vision blurred—Carmustine—malignant glioma	0.000521	0.00858	CcSEcCtD
Atomoxetine—Tremor—Carmustine—malignant glioma	0.000518	0.00853	CcSEcCtD
Atomoxetine—HTR2C—brain—malignant glioma	0.000518	0.00298	CbGeAlD
Atomoxetine—Back pain—Temozolomide—malignant glioma	0.000517	0.00851	CcSEcCtD
Atomoxetine—Warfarin—CYP2C18—malignant glioma	0.000512	0.0539	CrCbGaD
Atomoxetine—Agitation—Carmustine—malignant glioma	0.000508	0.00836	CcSEcCtD
Atomoxetine—Vision blurred—Temozolomide—malignant glioma	0.000504	0.00829	CcSEcCtD
Atomoxetine—Tremor—Temozolomide—malignant glioma	0.000501	0.00824	CcSEcCtD
Atomoxetine—Agitation—Temozolomide—malignant glioma	0.000491	0.00808	CcSEcCtD
Atomoxetine—SLC6A4—brain—malignant glioma	0.000491	0.00282	CbGeAlD
Atomoxetine—Vertigo—Temozolomide—malignant glioma	0.00048	0.0079	CcSEcCtD
Atomoxetine—Convulsion—Carmustine—malignant glioma	0.000479	0.00789	CcSEcCtD
Atomoxetine—Palpitations—Temozolomide—malignant glioma	0.000472	0.00777	CcSEcCtD
Atomoxetine—Myalgia—Carmustine—malignant glioma	0.000471	0.00775	CcSEcCtD
Atomoxetine—Chest pain—Carmustine—malignant glioma	0.000471	0.00775	CcSEcCtD
Atomoxetine—Anxiety—Carmustine—malignant glioma	0.000469	0.00772	CcSEcCtD
Atomoxetine—Diphenylpyraline—SLC6A3—malignant glioma	0.000467	0.0492	CrCbGaD
Atomoxetine—Cough—Temozolomide—malignant glioma	0.000467	0.00767	CcSEcCtD
Atomoxetine—Convulsion—Temozolomide—malignant glioma	0.000463	0.00762	CcSEcCtD
Atomoxetine—Arthralgia—Temozolomide—malignant glioma	0.000455	0.00749	CcSEcCtD
Atomoxetine—Myalgia—Temozolomide—malignant glioma	0.000455	0.00749	CcSEcCtD
Atomoxetine—Anxiety—Temozolomide—malignant glioma	0.000454	0.00746	CcSEcCtD
Atomoxetine—HTR2A—medulla oblongata—malignant glioma	0.000453	0.0026	CbGeAlD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000452	0.00744	CcSEcCtD
Atomoxetine—Infection—Carmustine—malignant glioma	0.000449	0.00738	CcSEcCtD
Atomoxetine—Dry mouth—Temozolomide—malignant glioma	0.000445	0.00732	CcSEcCtD
Atomoxetine—Tachycardia—Carmustine—malignant glioma	0.000441	0.00725	CcSEcCtD
Atomoxetine—Duloxetine—SLC6A3—malignant glioma	0.000436	0.0459	CrCbGaD
Atomoxetine—Infection—Temozolomide—malignant glioma	0.000433	0.00713	CcSEcCtD
Atomoxetine—SLC6A2—brain—malignant glioma	0.000432	0.00249	CbGeAlD
Atomoxetine—Anorexia—Carmustine—malignant glioma	0.00043	0.00708	CcSEcCtD
Atomoxetine—Nervous system disorder—Temozolomide—malignant glioma	0.000428	0.00704	CcSEcCtD
Atomoxetine—Skin disorder—Temozolomide—malignant glioma	0.000424	0.00697	CcSEcCtD
Atomoxetine—Hyperhidrosis—Temozolomide—malignant glioma	0.000422	0.00694	CcSEcCtD
Atomoxetine—Fluoxetine—CYP2B6—malignant glioma	0.000417	0.0439	CrCbGaD
Atomoxetine—Anorexia—Temozolomide—malignant glioma	0.000416	0.00684	CcSEcCtD
Atomoxetine—HTR2A—midbrain—malignant glioma	0.000414	0.00238	CbGeAlD
Atomoxetine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000411	0.00677	CcSEcCtD
Atomoxetine—Insomnia—Carmustine—malignant glioma	0.000408	0.00672	CcSEcCtD
Atomoxetine—Paraesthesia—Carmustine—malignant glioma	0.000405	0.00667	CcSEcCtD
Atomoxetine—HTR2A—spinal cord—malignant glioma	0.000404	0.00232	CbGeAlD
Atomoxetine—Somnolence—Carmustine—malignant glioma	0.000401	0.0066	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000398	0.00654	CcSEcCtD
Atomoxetine—Insomnia—Temozolomide—malignant glioma	0.000395	0.00649	CcSEcCtD
Atomoxetine—Decreased appetite—Carmustine—malignant glioma	0.000393	0.00646	CcSEcCtD
Atomoxetine—Paraesthesia—Temozolomide—malignant glioma	0.000392	0.00645	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Carmustine—malignant glioma	0.00039	0.00641	CcSEcCtD
Atomoxetine—Ephedrine—BCHE—malignant glioma	0.00039	0.0411	CrCbGaD
Atomoxetine—Somnolence—Temozolomide—malignant glioma	0.000388	0.00638	CcSEcCtD
Atomoxetine—Constipation—Carmustine—malignant glioma	0.000386	0.00635	CcSEcCtD
Atomoxetine—Pain—Carmustine—malignant glioma	0.000386	0.00635	CcSEcCtD
Atomoxetine—Dyspepsia—Temozolomide—malignant glioma	0.000384	0.00632	CcSEcCtD
Atomoxetine—Decreased appetite—Temozolomide—malignant glioma	0.000379	0.00624	CcSEcCtD
Atomoxetine—Ketoprofen—CXCL8—malignant glioma	0.000378	0.0398	CrCbGaD
Atomoxetine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000377	0.0062	CcSEcCtD
Atomoxetine—Fatigue—Temozolomide—malignant glioma	0.000376	0.00619	CcSEcCtD
Atomoxetine—Pain—Temozolomide—malignant glioma	0.000373	0.00614	CcSEcCtD
Atomoxetine—Constipation—Temozolomide—malignant glioma	0.000373	0.00614	CcSEcCtD
Atomoxetine—Feeling abnormal—Carmustine—malignant glioma	0.000372	0.00612	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Carmustine—malignant glioma	0.000369	0.00607	CcSEcCtD
Atomoxetine—Feeling abnormal—Temozolomide—malignant glioma	0.00036	0.00591	CcSEcCtD
Atomoxetine—Benzatropine—SLC6A3—malignant glioma	0.000358	0.0377	CrCbGaD
Atomoxetine—Body temperature increased—Carmustine—malignant glioma	0.000357	0.00587	CcSEcCtD
Atomoxetine—Abdominal pain—Carmustine—malignant glioma	0.000357	0.00587	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Temozolomide—malignant glioma	0.000357	0.00587	CcSEcCtD
Atomoxetine—Urticaria—Temozolomide—malignant glioma	0.000347	0.0057	CcSEcCtD
Atomoxetine—Abdominal pain—Temozolomide—malignant glioma	0.000345	0.00567	CcSEcCtD
Atomoxetine—Body temperature increased—Temozolomide—malignant glioma	0.000345	0.00567	CcSEcCtD
Atomoxetine—Maprotiline—SLC6A3—malignant glioma	0.000332	0.035	CrCbGaD
Atomoxetine—HTR2A—central nervous system—malignant glioma	0.000327	0.00188	CbGeAlD
Atomoxetine—Fenoprofen—PTGS1—malignant glioma	0.000327	0.0344	CrCbGaD
Atomoxetine—Asthenia—Carmustine—malignant glioma	0.000324	0.00533	CcSEcCtD
Atomoxetine—HTR2A—cerebellum—malignant glioma	0.00032	0.00184	CbGeAlD
Atomoxetine—Asthenia—Temozolomide—malignant glioma	0.000313	0.00515	CcSEcCtD
Atomoxetine—Modafinil—CYP2B6—malignant glioma	0.000311	0.0328	CrCbGaD
Atomoxetine—Diarrhoea—Carmustine—malignant glioma	0.000309	0.00508	CcSEcCtD
Atomoxetine—Pruritus—Temozolomide—malignant glioma	0.000309	0.00508	CcSEcCtD
Atomoxetine—Pseudoephedrine—SLC6A3—malignant glioma	0.000308	0.0325	CrCbGaD
Atomoxetine—CYP3A4—central nervous system—malignant glioma	0.000303	0.00174	CbGeAlD
Atomoxetine—Dizziness—Carmustine—malignant glioma	0.000299	0.00491	CcSEcCtD
Atomoxetine—Diarrhoea—Temozolomide—malignant glioma	0.000299	0.00491	CcSEcCtD
Atomoxetine—CYP2D6—central nervous system—malignant glioma	0.000298	0.00171	CbGeAlD
Atomoxetine—CYP2D6—cerebellum—malignant glioma	0.000292	0.00168	CbGeAlD
Atomoxetine—Diphenhydramine—CYP2C18—malignant glioma	0.000291	0.0307	CrCbGaD
Atomoxetine—Dizziness—Temozolomide—malignant glioma	0.000289	0.00475	CcSEcCtD
Atomoxetine—Vomiting—Carmustine—malignant glioma	0.000287	0.00472	CcSEcCtD
Atomoxetine—Pseudoephedrine—TNF—malignant glioma	0.000287	0.0302	CrCbGaD
Atomoxetine—Rash—Carmustine—malignant glioma	0.000285	0.00468	CcSEcCtD
Atomoxetine—Dermatitis—Carmustine—malignant glioma	0.000284	0.00468	CcSEcCtD
Atomoxetine—Headache—Carmustine—malignant glioma	0.000283	0.00465	CcSEcCtD
Atomoxetine—Methadone—CYP2C18—malignant glioma	0.000281	0.0296	CrCbGaD
Atomoxetine—Vomiting—Temozolomide—malignant glioma	0.000277	0.00456	CcSEcCtD
Atomoxetine—Rash—Temozolomide—malignant glioma	0.000275	0.00453	CcSEcCtD
Atomoxetine—Dermatitis—Temozolomide—malignant glioma	0.000275	0.00452	CcSEcCtD
Atomoxetine—Headache—Temozolomide—malignant glioma	0.000273	0.0045	CcSEcCtD
Atomoxetine—Benzphetamine—CYP2B6—malignant glioma	0.00027	0.0284	CrCbGaD
Atomoxetine—Nausea—Carmustine—malignant glioma	0.000268	0.00441	CcSEcCtD
Atomoxetine—Modafinil—SLC6A3—malignant glioma	0.000265	0.0279	CrCbGaD
Atomoxetine—HTR2A—brain—malignant glioma	0.00026	0.00149	CbGeAlD
Atomoxetine—Desipramine—CYP2C18—malignant glioma	0.000259	0.0273	CrCbGaD
Atomoxetine—Nausea—Temozolomide—malignant glioma	0.000259	0.00426	CcSEcCtD
Atomoxetine—CYP2D6—brain—malignant glioma	0.000237	0.00136	CbGeAlD
Atomoxetine—Benzphetamine—SLC6A3—malignant glioma	0.00023	0.0242	CrCbGaD
Atomoxetine—Diphenhydramine—CYP2B6—malignant glioma	0.000216	0.0228	CrCbGaD
Atomoxetine—Methadone—CYP2B6—malignant glioma	0.000209	0.022	CrCbGaD
Atomoxetine—Orphenadrine—CYP2B6—malignant glioma	0.000204	0.0215	CrCbGaD
Atomoxetine—Ketoprofen—PTGS1—malignant glioma	0.000193	0.0203	CrCbGaD
Atomoxetine—Desipramine—CYP2B6—malignant glioma	0.000193	0.0203	CrCbGaD
Atomoxetine—Fenoprofen—PTGS2—malignant glioma	0.000187	0.0197	CrCbGaD
Atomoxetine—Desipramine—SLC6A3—malignant glioma	0.000164	0.0173	CrCbGaD
Atomoxetine—Nortriptyline—PTGS1—malignant glioma	0.000154	0.0162	CrCbGaD
Atomoxetine—Diphenhydramine—PTGS1—malignant glioma	0.000142	0.015	CrCbGaD
Atomoxetine—Ketoprofen—PTGS2—malignant glioma	0.00011	0.0116	CrCbGaD
Atomoxetine—HTR2C—Signaling by GPCR—RAF1—malignant glioma	1.4e-05	0.000155	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS1—malignant glioma	1.4e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTPN11—malignant glioma	1.4e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CD80—malignant glioma	1.39e-05	0.000154	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.39e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APC—malignant glioma	1.39e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CG—malignant glioma	1.39e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—malignant glioma	1.38e-05	0.000153	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGF—malignant glioma	1.37e-05	0.000152	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTT1—malignant glioma	1.37e-05	0.000152	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CB—malignant glioma	1.37e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTPN11—malignant glioma	1.37e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CD—malignant glioma	1.36e-05	0.00015	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—IDH2—malignant glioma	1.36e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PDGFRA—malignant glioma	1.36e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—BRAF—malignant glioma	1.35e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BRAF—malignant glioma	1.34e-05	0.000147	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SPP1—malignant glioma	1.32e-05	0.000146	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL8—malignant glioma	1.31e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP3—malignant glioma	1.31e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT2—malignant glioma	1.31e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CB—malignant glioma	1.31e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BRAF—malignant glioma	1.31e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—malignant glioma	1.3e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT2—malignant glioma	1.3e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN2B—malignant glioma	1.3e-05	0.000144	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—BCHE—malignant glioma	1.3e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—malignant glioma	1.29e-05	0.000143	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS1—malignant glioma	1.29e-05	0.000142	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC5A5—malignant glioma	1.28e-05	0.000142	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2B6—malignant glioma	1.28e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT2—malignant glioma	1.27e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—malignant glioma	1.27e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTK2—malignant glioma	1.26e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CD—malignant glioma	1.26e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL8—malignant glioma	1.26e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—malignant glioma	1.26e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TERT—malignant glioma	1.25e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CD—malignant glioma	1.25e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PIK3CA—malignant glioma	1.25e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HES1—malignant glioma	1.24e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PIK3CA—malignant glioma	1.24e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NCOR1—malignant glioma	1.23e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—KRAS—malignant glioma	1.23e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CD—malignant glioma	1.22e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—KRAS—malignant glioma	1.22e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PDGFB—malignant glioma	1.22e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—RAF1—malignant glioma	1.22e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGFR1—malignant glioma	1.21e-05	0.000134	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.21e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PIK3CA—malignant glioma	1.21e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FGF2—malignant glioma	1.2e-05	0.000133	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.2e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—malignant glioma	1.2e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—KRAS—malignant glioma	1.2e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HIF1A—malignant glioma	1.2e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FGF2—malignant glioma	1.2e-05	0.000132	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—BCHE—malignant glioma	1.2e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CB—malignant glioma	1.19e-05	0.000131	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC5A5—malignant glioma	1.18e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDGFRA—malignant glioma	1.18e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FGF2—malignant glioma	1.17e-05	0.000129	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—IDH1—malignant glioma	1.17e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CAV1—malignant glioma	1.16e-05	0.000128	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SPP1—malignant glioma	1.15e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KDR—malignant glioma	1.14e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL8—malignant glioma	1.14e-05	0.000126	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SPHK1—malignant glioma	1.13e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PIK3CA—malignant glioma	1.13e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MDM2—malignant glioma	1.13e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RAF1—malignant glioma	1.12e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PIK3CA—malignant glioma	1.12e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MDM2—malignant glioma	1.12e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RAF1—malignant glioma	1.11e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB2—malignant glioma	1.11e-05	0.000123	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2C18—malignant glioma	1.11e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB2—malignant glioma	1.1e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FN1—malignant glioma	1.1e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—F2—malignant glioma	1.1e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PIK3CA—malignant glioma	1.1e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CB—malignant glioma	1.1e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MDM2—malignant glioma	1.1e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RAF1—malignant glioma	1.09e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—malignant glioma	1.09e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CB—malignant glioma	1.09e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BAD—malignant glioma	1.09e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TERT—malignant glioma	1.09e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB2—malignant glioma	1.08e-05	0.000119	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOTCH1—malignant glioma	1.08e-05	0.000119	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CB—malignant glioma	1.07e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDGFB—malignant glioma	1.06e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CD80—malignant glioma	1.06e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGFR1—malignant glioma	1.05e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CG—malignant glioma	1.05e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APC—malignant glioma	1.05e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL8—malignant glioma	1.05e-05	0.000116	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.05e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL8—malignant glioma	1.05e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGF—malignant glioma	1.04e-05	0.000115	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HIF1A—malignant glioma	1.04e-05	0.000115	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTPN11—malignant glioma	1.04e-05	0.000114	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—malignant glioma	1.03e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL8—malignant glioma	1.02e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—malignant glioma	1.02e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—malignant glioma	1.01e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—malignant glioma	1.01e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—malignant glioma	1.01e-05	0.000111	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAT—malignant glioma	1.01e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CAV1—malignant glioma	1e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—malignant glioma	1e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—malignant glioma	1e-05	0.00011	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KDR—malignant glioma	9.94e-06	0.00011	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—malignant glioma	9.91e-06	0.000109	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—malignant glioma	9.89e-06	0.000109	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—malignant glioma	9.8e-06	0.000108	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—malignant glioma	9.79e-06	0.000108	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT2—malignant glioma	9.65e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—malignant glioma	9.6e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—F2—malignant glioma	9.57e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FN1—malignant glioma	9.57e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—malignant glioma	9.53e-06	0.000105	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—malignant glioma	9.51e-06	0.000105	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NCOR1—malignant glioma	9.5e-06	0.000105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—malignant glioma	9.48e-06	0.000105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—malignant glioma	9.46e-06	0.000104	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BAD—malignant glioma	9.45e-06	0.000104	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—malignant glioma	9.41e-06	0.000104	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOTCH1—malignant glioma	9.36e-06	0.000103	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CD—malignant glioma	9.27e-06	0.000102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—malignant glioma	9.26e-06	0.000102	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAT—malignant glioma	9.26e-06	0.000102	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—malignant glioma	9.25e-06	0.000102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—malignant glioma	9.21e-06	0.000102	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—malignant glioma	9.18e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—malignant glioma	9.18e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CD80—malignant glioma	9.17e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APC—malignant glioma	9.15e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—malignant glioma	9.15e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—malignant glioma	9.07e-06	0.0001	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGF—malignant glioma	9.05e-06	9.99e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTPN11—malignant glioma	8.99e-06	9.93e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—malignant glioma	8.99e-06	9.92e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—malignant glioma	8.97e-06	9.91e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGF2—malignant glioma	8.87e-06	9.8e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NCOR1—malignant glioma	8.74e-06	9.65e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—malignant glioma	8.6e-06	9.5e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—malignant glioma	8.56e-06	9.45e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—malignant glioma	8.5e-06	9.38e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—malignant glioma	8.48e-06	9.36e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—malignant glioma	8.41e-06	9.29e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS1—malignant glioma	8.41e-06	9.28e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT2—malignant glioma	8.38e-06	9.25e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—malignant glioma	8.34e-06	9.21e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	8.34e-06	9.2e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—malignant glioma	8.32e-06	9.19e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MDM2—malignant glioma	8.3e-06	9.17e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RAF1—malignant glioma	8.27e-06	9.14e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—malignant glioma	8.24e-06	9.1e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—malignant glioma	8.19e-06	9.04e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	8.08e-06	8.92e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	8.05e-06	8.89e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	7.97e-06	8.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—malignant glioma	7.88e-06	8.7e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—malignant glioma	7.88e-06	8.7e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—malignant glioma	7.82e-06	8.63e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BCHE—malignant glioma	7.82e-06	8.63e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL8—malignant glioma	7.76e-06	8.57e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAV1—malignant glioma	7.75e-06	8.55e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC5A5—malignant glioma	7.72e-06	8.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGF2—malignant glioma	7.71e-06	8.51e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—malignant glioma	7.7e-06	8.51e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—malignant glioma	7.65e-06	8.45e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—malignant glioma	7.65e-06	8.44e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	7.5e-06	8.28e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—malignant glioma	7.49e-06	8.27e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—malignant glioma	7.43e-06	8.2e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—malignant glioma	7.42e-06	8.19e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.4e-06	8.17e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—malignant glioma	7.28e-06	8.04e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	7.24e-06	7.99e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—malignant glioma	7.22e-06	7.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MDM2—malignant glioma	7.21e-06	7.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RAF1—malignant glioma	7.18e-06	7.93e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAV1—malignant glioma	7.13e-06	7.87e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—malignant glioma	7.11e-06	7.85e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—malignant glioma	7.07e-06	7.81e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—malignant glioma	7.06e-06	7.79e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—malignant glioma	7.02e-06	7.75e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	7.01e-06	7.75e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—malignant glioma	6.98e-06	7.71e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—malignant glioma	6.81e-06	7.52e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—malignant glioma	6.81e-06	7.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL8—malignant glioma	6.74e-06	7.44e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—malignant glioma	6.69e-06	7.38e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—malignant glioma	6.64e-06	7.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	6.51e-06	7.19e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—malignant glioma	6.5e-06	7.17e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—malignant glioma	6.49e-06	7.17e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—malignant glioma	6.47e-06	7.14e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—malignant glioma	6.45e-06	7.12e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—malignant glioma	6.44e-06	7.11e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—malignant glioma	6.42e-06	7.09e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—malignant glioma	6.3e-06	6.96e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—malignant glioma	6.29e-06	6.94e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—malignant glioma	6.26e-06	6.92e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—malignant glioma	6.24e-06	6.89e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—malignant glioma	6.22e-06	6.87e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CD—malignant glioma	6.2e-06	6.85e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—malignant glioma	6.1e-06	6.73e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—malignant glioma	6.06e-06	6.69e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAT—malignant glioma	6.05e-06	6.68e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—malignant glioma	5.91e-06	6.53e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—malignant glioma	5.8e-06	6.4e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOR1—malignant glioma	5.71e-06	6.31e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CD—malignant glioma	5.71e-06	6.3e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—malignant glioma	5.67e-06	6.26e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—malignant glioma	5.47e-06	6.05e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—malignant glioma	5.46e-06	6.03e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—malignant glioma	5.42e-06	5.99e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—malignant glioma	5.42e-06	5.99e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CB—malignant glioma	5.41e-06	5.97e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—malignant glioma	5.36e-06	5.92e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—malignant glioma	5.36e-06	5.92e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—malignant glioma	5.31e-06	5.86e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—malignant glioma	5.04e-06	5.56e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CB—malignant glioma	4.97e-06	5.49e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—malignant glioma	4.93e-06	5.44e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—malignant glioma	4.93e-06	5.44e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	4.92e-06	5.44e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—malignant glioma	4.76e-06	5.26e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—malignant glioma	4.67e-06	5.16e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAV1—malignant glioma	4.66e-06	5.14e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—malignant glioma	4.65e-06	5.14e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—malignant glioma	4.3e-06	4.75e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	4.28e-06	4.72e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—malignant glioma	4.24e-06	4.69e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—malignant glioma	4.14e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—malignant glioma	4.1e-06	4.52e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—malignant glioma	4.02e-06	4.44e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CD—malignant glioma	3.73e-06	4.12e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—malignant glioma	3.49e-06	3.86e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—malignant glioma	3.3e-06	3.64e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CB—malignant glioma	3.25e-06	3.59e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—malignant glioma	3.22e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—malignant glioma	3.03e-06	3.35e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—malignant glioma	2.81e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—malignant glioma	2.69e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—malignant glioma	2.48e-06	2.73e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.98e-06	2.19e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—malignant glioma	1.62e-06	1.79e-05	CbGpPWpGaD
